• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可穿戴式心脏复律除颤器缩短心肌梗死后左心室功能不全患者的住院时间:一项单中心真实世界经验

Wearable Cardioverter Defibrillator Shortens the Lengths of Stay in Patients with Left Ventricular Dysfunction after Myocardial Infarction: A Single-Centre Real-World Experience.

作者信息

Cardelli Laura Sofia, Delbaere Quentin, Massin François, Granier Mathieu, Casella Gianni, Barbato Gaetano, Dupasquier Valentin, Macia Jean-Christophe, Leclercq Florence, Pasquie Jean-Luc, Roubille François

机构信息

Cardiology Department, Ospedale Maggiore, 40100 Bologna, Italy.

Cardiology Department, Arnaud-De-Villeneuve Hospital, 34090 Montpellier, France.

出版信息

J Clin Med. 2023 Jul 25;12(15):4884. doi: 10.3390/jcm12154884.

DOI:10.3390/jcm12154884
PMID:37568286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10419391/
Abstract

The wearable cardioverter defibrillator (WCD) has been proven to be effective in preventing sudden cardiac death (SCD) in patients soon after acute myocardial infarction (AMI) and left ventricular ejection fraction (LVEF) ≤35%. The aim of this study was to assess whether a WCD may shorten the length of an initial hospital stay (total length, days in the intensive care unit (ICU) and in the acute cardiac care unit (ACCU)) among these patients. This was a single-centre, retrospective observational study of patients referred for the management of SCD risk post-AMI and LVEF ≤35%, in a tertiary care hospital. The clinical characteristics and length of index hospitalization of the group of patients discharged, with or without WCD, were compared. A propensity score analysis was performed, then weighted regression models were conducted. A total of 101 patients in the WCD group and 29 in the control group were enrolled in the analysis. In the weighted regression models, WCD significantly reduced the days spent in ACCU ( < 0.001). WCD patients had significantly fewer days spent in ACCU (5.5 ± 2.6 vs. 8.4 ± 12.8 days, < 0.001) and shorter hospitalizations (10.2 ± 5.7 vs. 13.4 ± 17.6 days, = 0.005), compared with the control group. It was concluded that the WCD appears to reduce the total length of hospitalization and lengths of stay in ACCU for patients post-AMI and with left ventricular dysfunction.

摘要

可穿戴式心脏复律除颤器(WCD)已被证明在预防急性心肌梗死(AMI)后不久且左心室射血分数(LVEF)≤35%的患者心脏性猝死(SCD)方面有效。本研究的目的是评估WCD是否可缩短这些患者首次住院的时长(总时长、在重症监护病房(ICU)和急性心脏护理病房(ACCU)的天数)。这是一项在三级医院对因AMI后SCD风险及LVEF≤35%而转诊的患者进行的单中心回顾性观察研究。比较了出院时使用或未使用WCD的患者组的临床特征和索引住院时长。进行了倾向评分分析,然后构建了加权回归模型。分析纳入了WCD组的101例患者和对照组的29例患者。在加权回归模型中,WCD显著减少了在ACCU的天数(<0.001)。与对照组相比,使用WCD的患者在ACCU的天数显著更少(5.5±2.6天对8.4±12.8天,<0.001),住院时间更短(10.2±5.7天对13.4±17.6天,=0.005)。得出的结论是,WCD似乎可减少AMI后左心室功能不全患者的总住院时长和在ACCU的住院时长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d08/10419391/212533cfd9bf/jcm-12-04884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d08/10419391/212533cfd9bf/jcm-12-04884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d08/10419391/212533cfd9bf/jcm-12-04884-g001.jpg

相似文献

1
Wearable Cardioverter Defibrillator Shortens the Lengths of Stay in Patients with Left Ventricular Dysfunction after Myocardial Infarction: A Single-Centre Real-World Experience.可穿戴式心脏复律除颤器缩短心肌梗死后左心室功能不全患者的住院时间:一项单中心真实世界经验
J Clin Med. 2023 Jul 25;12(15):4884. doi: 10.3390/jcm12154884.
2
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.穿戴式心脏除颤器在心肌梗死后早期被认为高危患者中的应用。
J Am Coll Cardiol. 2013 Nov 19;62(21):2000-2007. doi: 10.1016/j.jacc.2013.05.086. Epub 2013 Jul 31.
3
The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital.可穿戴式除颤器的使用对半农村地区急性护理医院植入心脏除颤器的长期决策的影响。
J Interv Card Electrophysiol. 2021 Nov;62(2):401-407. doi: 10.1007/s10840-020-00898-5. Epub 2020 Nov 17.
4
Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.心梗后严重左心室功能受损患者中可穿戴式除颤器治疗电风暴的疗效:病例报告。
J Med Case Rep. 2021 May 17;15(1):243. doi: 10.1186/s13256-021-02833-2.
5
Wearable cardioverter defibrillator after cardiac surgery: Analysis of real-life data from patients at transient risk of sudden cardiac death.心脏手术后可穿戴除颤器:对有短暂性心源性猝死风险的患者进行真实数据的分析。
Ann Noninvasive Electrocardiol. 2023 Mar;28(2):e13048. doi: 10.1111/anec.13048. Epub 2023 Feb 1.
6
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.左心室功能障碍患者冠状动脉血运重建术后的早期死亡率风险及可穿戴式除颤器的潜在作用。
Circ Arrhythm Electrophysiol. 2013 Feb;6(1):117-28. doi: 10.1161/CIRCEP.112.973552. Epub 2012 Dec 28.
7
Prevention of Early Sudden Cardiac Death after Myocardial Infarction Using the Wearable Cardioverter Defibrillator-Results from a Real-World Cohort.使用可穿戴式心脏复律除颤器预防心肌梗死后早期心源性猝死——来自真实世界队列的结果
J Clin Med. 2023 Jul 31;12(15):5029. doi: 10.3390/jcm12155029.
8
Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days ≥90 Wear Days.比较穿戴式心脏除颤器(WCD)保护患者的结果,(WCD)佩戴时间<90 天和≥90 天。
In Vivo. 2020 Nov-Dec;34(6):3601-3610. doi: 10.21873/invivo.12205.
9
Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.围生期心肌病伴严重左心室功能障碍患者发生心室颤动的风险-可穿戴式除颤器的价值。
Eur J Heart Fail. 2014 Dec;16(12):1331-6. doi: 10.1002/ejhf.188. Epub 2014 Nov 5.
10
The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?可穿戴式心脏复律除颤器作为心肌梗死后植入式除颤器的桥梁:我们了解多少?
Expert Rev Med Devices. 2016 Jul;13(7):627-32. doi: 10.1080/17434440.2016.1200969. Epub 2016 Jun 27.

引用本文的文献

1
Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England.英国心肌梗死后有心脏性猝死风险患者使用LifeVest®的成本效用分析。
Pharmacoecon Open. 2025 Mar;9(2):301-312. doi: 10.1007/s41669-024-00553-z. Epub 2025 Jan 24.
2
Appropriate use of wearable defibrillators with multiparametric evaluation to avoid unnecessary defibrillator implantation.恰当使用带有多参数评估的可穿戴除颤器,以避免不必要的除颤器植入。
Open Heart. 2024 Sep 18;11(2):e002787. doi: 10.1136/openhrt-2024-002787.

本文引用的文献

1
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.2022年欧洲心脏病学会室性心律失常患者管理和心脏性猝死预防指南
Eur Heart J. 2022 Oct 21;43(40):3997-4126. doi: 10.1093/eurheartj/ehac262.
2
Cardiac Critical Care: The Evolution of a Novel Subspecialty.心脏危重症医学:一个新兴亚专科的演进。
Methodist Debakey Cardiovasc J. 2022 Jun 3;18(3):24-29. doi: 10.14797/mdcvj.1092. eCollection 2022.
3
The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective.
可穿戴式心脏除颤器在近期心肌梗死成年患者中的应用价值:从卫生技术评估角度看其经济学和临床意义。
Int J Cardiol. 2022 Jun 1;356:12-18. doi: 10.1016/j.ijcard.2022.04.003. Epub 2022 Apr 5.
4
Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe.急性冠状动脉综合征的患者特征、治疗策略、预后及住院费用:来自中欧一家大型高容量中心的3年数据
Eur Heart J Suppl. 2022 Mar 30;24(Suppl B):B3-B9. doi: 10.1093/eurheartjsupp/suac001. eCollection 2022 Apr.
5
When is a wearable defibrillator indicated?何时需要使用可穿戴除颤器?
Expert Rev Med Devices. 2021 Dec;18(sup1):51-56. doi: 10.1080/17434440.2021.2019013. Epub 2021 Dec 20.
6
Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing ICD explant procedures: Clinical and economic implications.可穿戴式心脏除颤器在接受 ICD 除颤器取出术的成年患者中的成本最小化分析:临床和经济意义。
Clin Cardiol. 2021 Nov;44(11):1497-1505. doi: 10.1002/clc.23709. Epub 2021 Aug 24.
7
Long-Term Outcomes of Patients With Late Presentation of ST-Segment Elevation Myocardial Infarction.ST 段抬高型心肌梗死患者晚期就诊的长期结局。
J Am Coll Cardiol. 2021 Apr 20;77(15):1859-1870. doi: 10.1016/j.jacc.2021.02.041.
8
Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis.用于预防心源性猝死的可穿戴式心脏复律除颤器:一项荟萃分析。
J Innov Card Rhythm Manag. 2018 May 15;9(5):3151-3162. doi: 10.19102/icrm.2018.090506. eCollection 2018 May.
9
Mortality and Costs Associated with Wearable Cardioverter-defibrillators after Acute Myocardial Infarction: A Retrospective Cohort Analysis of Medicare Claims Data.急性心肌梗死后可穿戴式心脏复律除颤器相关的死亡率和成本:基于医疗保险索赔数据的回顾性队列分析
J Innov Card Rhythm Manag. 2019 Oct 15;10(10):3866-3873. doi: 10.19102/icrm.2019.101007. eCollection 2019 Oct.
10
Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses.可穿戴式除颤器依从性对 VEST 试验结果的影响:按治疗分析和意向性分析。
J Cardiovasc Electrophysiol. 2020 May;31(5):1009-1018. doi: 10.1111/jce.14404. Epub 2020 Mar 3.